Cargando…
Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev(®)) in South Korea, 2015–2019
INTRODUCTION: The live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV; Imojev(®)) has been approved in South Korea for use in subjects aged ≥ 12 months since 2015. As part of the license agreement, a post-marketing surveillance study was undertaken to actively monitor the safety prof...
Autores principales: | Kim, Hee Soo, Oh, Yongho, Korejwo, Joanna, Castells, Valérie Bosch, Yang, Kuhyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452989/ https://www.ncbi.nlm.nih.gov/pubmed/32474892 http://dx.doi.org/10.1007/s40121-020-00305-6 |
Ejemplares similares
-
Post-Marketing Surveillance of Hepatitis A Virus Vaccine (Avaxim(®) 160U) in South Korea from 2011 to 2015
por: Kim, HeeSoo, et al.
Publicado: (2019) -
A randomized study of the immunogenicity and safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in comparison with SA14-14-2 Vaccine in children in the Republic of Korea
por: Kim, Dong Soo, et al.
Publicado: (2014) -
The present and future of veterinary vaccines for Japanese encephalitis in Korea
por: Nah, Jin-Ju, et al.
Publicado: (2015) -
Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea
por: Kwak, Byung Ok, et al.
Publicado: (2021) -
Reemergence of Japanese Encephalitis in South Korea, 2010–2015
por: Sunwoo, Jun-Sang, et al.
Publicado: (2016)